Da Liu, Min Qiu, Lili Jiang, Kuiran Liu
The functions of Long noncoding RNA (lncRNA) HOXB-AS1 have been investigated in glioblastoma and multiple myeloma. However, the role of lncRNA HOXB-AS1 in endometrial carcinoma (EC) remains largely unknown. This study investigated the underlying mechanisms of the lncRNA HOXB-AS1 on the progression of EC. In this study, We found that HOXB-AS1 expression was significantly upregulated in EC tissue samples and was associated with shorter survival time. Furthermore, upregulation of HOXB-AS1 promoted proliferation, invasion, and migration of EC cell...
January 2020: Technology in Cancer Research & Treatment
Laura Van Moortel, Kris Gevaert, Karolien De Bosscher
Exogenous glucocorticoids are widely used in the clinic for the treatment of inflammatory disorders and hematological cancers. Unfortunately, their use is associated with debilitating side effects, including hyperglycemia, osteoporosis, mood swings, and weight gain. Despite the continued efforts of pharma as well as academia, the search for so-called selective glucocorticoid receptor modulators (SEGRMs), compounds with strong anti-inflammatory or anti-cancer properties but a reduced number or level of side effects, has had limited success so far...
2020: Frontiers in Endocrinology
Aveen N Adham, Sara Abdelfatah, Alaadin M Naqishbandi, Nuha Mahmoud, Thomas Efferth
BACKGROUND: Apigenin is one of the most abundant dietary flavonoids that possesses multiple bio-functions. PURPOSE: This study was designed to determine the influence of apigenin on gene expressions, cancer cells, as well as STAT1/COX-2/iNOS pathway mediated inflammation and tumorigenesis in HEK293-STAT1 cells. Furthermore, the cytotoxic activity toward multiple myeloma (MM) cell lines was investigated. METHODS: Bioinformatic analyses were used to predict the sensitivity and resistance of tumor cells toward apigenin and to determine cellular pathways influenced by this compound...
October 8, 2020: Phytomedicine
Thejus T Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E Wegner, Santhosh Sadashiv
BACKGROUND: Disparities driven by socioeconomic factors have been shown to impact outcomes for cancer patients. We sought to explore this relationship among patients with multiple myeloma (MM) who were not considered for hematopoietic stem cell transplant in the first-line setting and how it varied over time. METHODS: We queried the National Cancer Database for patients diagnosed with MM between 2004 and 2016 and included only those who received systemic therapy as the first-line treatment...
October 10, 2020: Hematology/oncology and Stem Cell Therapy
Ciara Tierney, Despina Bazou, Giao Lê, Paul Dowling, Peter O Gorman
Multiple Myeloma (MM), the second most highly diagnosed lymphoid cancer worldwide, is characterised by the uninhibited proliferation of terminally differentiated B-lymphocytes. Leading to the production of monoclonal proteins (M proteins) and the development of CRAB features (hypercalcemia, renal impairment, anaemia and bone lesions), MM is considered incurable as the vast majority of patients eventually show a relapse in symptoms. MGUS (Monoclonal Gammopathy of Unknown Significance) is considered the premalignant form of MM and, although 93% of MM patients exhibit M protein production associated with MGUS before diagnosis, little is known about the switch from premalignant to malignant disease...
October 14, 2020: Journal of Proteomics
Miyuki Okura, Naoko Ida, Takahiro Yamauchi
Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of abnormal plasma cells in bone marrow. Flow cytometry distinguishes between normal and abnormal plasma cells by evaluating cluster of differentiation (CD) 56 and CD19 expression patterns. Moreover, immunophenotyping of mature plasma cell 1 (MPC-1) and very late antigen-5 (CD49e) identifies the maturity of MM as mature (MPC-1+ , CD49e+ ), intermediate (MPC-1+ , CD49e- ), or immature (MPC-1- , CD49e- ). We retrospectively examined the effects of surface marker expression and maturity subtype on overall survival (OS) and time to next treatment (TNT) among 55 patients (25 males, 30 females) with symptomatic MM...
October 17, 2020: Medical Oncology
Jia Li, Chengbin Wang, Qian Meng, Zhiying Hu, Mei Hu, Man Zhang
INTRODUCTION: Multiple myeloma (MM) is a hematological malignancy. It is of great clinical significance to screen microRNAs (miRNAs) in urine as noninvasive diagnostic biomarkers for MM. METHODS: Urinary miRNAs in MM were performed by Agilent Bioanalyzer 2100 and verified by quantitative real-time PCR (qRT-PCR). Receiver operator characteristic (ROC) was used to evaluate the diagnostic value of abnormal miRNAs for MM. Progression-free survival (PFS) of MM was calculated by Kaplan-Meier...
October 17, 2020: International Journal of Laboratory Hematology
Xiao-Han Li, Lei Xue, Hui Xu, Xu-Han Zhang, Xin Liu, Wei-Bo Zhu, Xing-Bing Wang
OBJECTIVE: To investigate the safety and efficacy of tumor-associated antigen-specific cytotoxic T lympho- cytes (TAA-CTL) in the treatment of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). METHODS: Peripheral blood mononuclear cells (PBMNC)of patients were collected. Dendritic cells (DC) were loaded with multiple tumor-associated antigens (TAA) (NY-ESO-1, MAGE-A3, MAGE-A4, WT1, Survivin, PRAME, LMP1 and LMP2A), then co-cultured with PBMNC to induce cytotoxic T lymphocytes (CTL)...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Na-Li Chu, Jing-Yu Zhang, Li Guo, Di Xu, Hong Fan
OBJECTIVE: To investigate the expression level and the clinical significance of serum interleukin-6(IL-6) , IL-10, tumor necrosis factor α(TNF-α) and β2 -microglobulin(β2 -MG) in multiple myeloma(MM) patients with different blood separation results. METHODS: The clinical data of 124 newly diagnosed MM patients (76 cases of IgG type, 48 cases of IgA type) treated in our hospital from October 2015 to October 2019 were enrolled and analyzed. The blood samples were divided into control group (the order from top to bottom is serum, separator gel and red blood cells) and abnormal group (the order from top to bottom is serum, red blood cells, separator gel and red blood cells) according to the blood separation result...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Guang-Zhou Wang, Zheng-Fang Wang, Jun Wang, Li Ma, Lin Zhou
OBJECTIVE: To explore the clinical value of serum bone turnover markers including β-CrossLaps (β-CTx), N-MID Osteocalcin (Osteocalcin), and total procollagen type 1 amino-terminal propeptide (TP1NP) in patients with myeloma bone disease (MBD). METHODS: A total of 55 MBD patients(MBD group) and 20 healthy volunteers(control group) were selected, and the serum was collected for detecting β-CTx, Osteocalcin and TP1NP by Roche analyzer of automated electrochemiluminescence...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Xiao-Rui Li, Xiao-Ming Fei, Yu Tang, Bing Lu, Yuan-Lin Yang, Li-Xia Wang
OBJECTIVE: To investigate the effect and possible mechanism of up-regulation of p-Akt by doxycycline (DOX) on myeloma cell line H929. METHODS: Multiple myeloma cell line H929 was treated with DOX at different concentrations for different times, and cell proliferation rate was measured by CCK-8 assay. The protein expression level of p-Akt, PTEN, p-PDK1, p-mTOR, p-GSK-3β, and p-BAD was analyzed by Western blot. The mRNA levels of mTOR, BCL-2, and NF-κB was analyzed by RT-PCR...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Xin Wang, Ying Wu, Lin Zhang, Yu-Xiang Li, Bing Han, Xue Shi, Wei Wang, Li-Sheng Wang
OBJECTIVE: To detect the expression of MutT homolog 1 (MTH1) in CD138-negative cells (CD138-) and CD138-positive cells (CD138+) cells of the patients with multiple myeloma (MM), and to explore the effect of MTH1 inhibitor TH588 on cell morphology, proliferation and apoptosis of MM cell U266. METHODS: CD138- and CD138+ cells of MM patients were isolated, and RNA was extracted. The expression of NUDT family was detected by Q-PCR. MM cell line U266 was used to observe the effect of IL-6 on MTH1 expression...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Yun-Yan Zan, Yang Liu, Yi DA, Jun-Ling Zhuang
OBJECTIVE: To explore the role of interaction between osteoclast stimulator stromal derived factor 1 alpha (SDF-1α) and osteoblast inhibitor dickkopf-1 (DKK-1) in the development of multiple myeloma (MM) bone disease. METHODS: The serum samples of 51 patients with newly diagnosed MM, 30 age-matched healthy controls, and 35 non-Hodgkin lymphoma patients from June 2011 to May 2014 in Peking Union Medical College Hospital were collected. The serum SDF-1α and DKK-1 were detected by ELISA...
October 2020: Zhongguo Shi Yan Xue Ye Xue za Zhi
Vania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Bart Heeg, Andrea Garcia, Annette Lam, Gerardo Machnicki, Jianming He, Mariana Fernandez
INTRODUCTION: The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). In Latin America, bortezomib- or thalidomide-based regimens remain standard of care (SoC) for this population. No head-to-head trials have compared D-VMP with SoC regimens used in Latin America...
October 16, 2020: Advances in Therapy
María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, Verónica González-Calle, Efstathios Kastritis, Roman Hajek, Carlos Fernández De Larrea, Gareth J Morgan, Giampaolo Merlini, Hartmut Goldschmidt, Catarina Geraldes, Alessandro Gozzetti, Charalampia Kyriakou, Laurent Garderet, Markus Hansson, Elena Zamagni, Dorotea Fantl, Xavier Leleu, Byung-Su Kim, Graça Esteves, Heinz Ludwig, Saad Usmani, Chang-Ki Min, Ming Qi, Jon Ukropec, Brendan M Weiss, S Vincent Rajkumar, Brian G M Durie, Jesús San-Miguel
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR: 2...
October 16, 2020: Blood Cancer Journal
Aya Yoshino, Shintaro Ishida, Shinsuke Nakamura, Ryosuke Kita, Mika Seto, Shinji Matsumoto, Morishige Takeshita, Seiji Kondo
Primary oral diffuse large B cell lymphoma (DLBCL) is rare and the differential diagnosis is difficult due to its low incidence and nonspecific symptoms, which resemble those of common oral diseases in the initial clinical setting. We aimed to discuss the value of making an accurate diagnosis using liquid-based cytology (LBC) and cell block (CB) for not only the morphological interpretation but also cytohistological assessment of oral DLBCL. LBC and CBs made from oral brushing materials were prepared on the first medical examination and a morphological analysis and immunohistochemical analysis of specific biomarkers were performed...
October 14, 2020: Diagnostics
Jennifer L Nicol, Carmel Woodrow, Nicola W Burton, Peter Mollee, Andrew J Nicol, Michelle M Hill, Tina L Skinner
People with multiple myeloma (MM) often experience disease symptoms and treatment toxicities that can be alleviated through physical activity (PA). However, the majority of people with MM are insufficiently active. This study explored PA among people with MM, including differences by treatment stage, symptoms and demographics, and programming preferences. Overall, 126 people with MM (77% response rate) completed the survey. Pre-diagnosis, 25.4% were sufficiently active, with 12.0% remaining active after treatment...
October 13, 2020: Journal of Clinical Medicine
Amro M Soliman, Teoh Seong Lin, Pasuk Mahakkanukrauh, Srijit Das
Multiple myeloma (MM) is a cancerous bone disease characterized by malignant transformation of plasma cells in the bone marrow. MM is considered to be the second most common blood malignancy, with 20,000 new cases reported every year in the USA. Extensive research is currently enduring to validate diagnostic and therapeutic means to manage MM. microRNAs (miRNAs) were shown to be dysregulated in MM cases and to have a potential role in either progression or suppression of MM. Therefore, researchers investigated miRNAs levels in MM plasma cells and created tools to test their impact on tumor growth...
October 13, 2020: International Journal of Molecular Sciences
Snehal M Gaikwad, Zaw Phyo, Anaisa Quintanilla Arteaga, Sayeh Gorjifard, David R Calabrese, Daniel Connors, Jing Huang, Aleksandra M Michalowski, Shuling Zhang, Zheng-Gang Liu, John S Schneekloth, Beverly A Mock
New approaches to target MYC include the stabilization of a guanine-rich, G-quadruplex (G4) tertiary DNA structure in the NHE III region of its promoter. Recent screening of a small molecule microarray platform identified a benzofuran, D089, that can stabilize the MYC G4 and inhibit its transcription. D089 induced both dose- and time-dependent multiple myeloma cell death mediated by endoplasmic reticulum induced stress. Unexpectedly, we uncovered two mechanisms of cell death: cellular senescence, as evidenced by increased levels of p16, p21 and γ-H2AX proteins and a caspase 3-independent mechanism consistent with pyroptosis...
October 13, 2020: Cancers
Hongzhao Lu, Meichen Yin, Ling Wang, Jia Cheng, Wei Cheng, Huanping An, Tao Zhang
FGF13, a member of the FGF subfamily, has been found to be highly expressed in cancer cells such as prostate cancer, melanoma, glioma and multiple myeloma. However, the mechanism of FGF13 function during cancer cell proliferation remains to be unexplored, especially Non-small cell lung cancer (NSCLC). In this study, the cell proliferation effect of FGF13 on A549 cells was checked by CCK-8, clone formation, Ki67 immunofluorescence staining and Flow Cytometry assay. Localization of FGF13 within A549 cells was performed with confocal laser scanning microscope...
October 16, 2020: Cancer Biology & Therapy
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"